SUTRO BIOPHARMA, INC.

Fundamental score not available. AIR's fundamental engine is built for businesses with established revenue and cash flow; biotech financial profiles — often R&D-heavy or pre-revenue — don't yet fit the measures it requires. AIR still assesses this company on discovery, market confirmation and risk, at reduced overall confidence.

This month at a glance

Evidence timeline

1. [8-K 2.02] SUTRO BIOPHARMA, INC. — Results of Operations and Financial ConditionSEC · SEC EDGAR
   Aug 12, 2026 · 8-K
2. [8-K 2.02] SUTRO BIOPHARMA, INC. — Results of Operations and Financial ConditionSEC · SEC EDGAR
   May 14, 2026 · 8-K
3. [8-K 2.02] SUTRO BIOPHARMA, INC. — Results of Operations and Financial ConditionSEC · SEC EDGAR
   Mar 23, 2026 · 8-K
4. [8-K 1.02] SUTRO BIOPHARMA, INC. — Termination of a Material Definitive AgreementSEC · SEC EDGAR
   Mar 23, 2026 · 8-K
5. [8-K 1.01] SUTRO BIOPHARMA, INC. — Entry into a Material Definitive AgreementSEC · SEC EDGAR
   Feb 9, 2026 · 8-K
6. [8-K 8.01] SUTRO BIOPHARMA, INC. — Other EventsSEC · SEC EDGAR
   Dec 17, 2025 · 8-K
7. [8-K 3.03] SUTRO BIOPHARMA, INC. — Material Modification to Rights of Security HoldersSEC · SEC EDGAR
   Dec 1, 2025 · 8-K
8. [8-K 8.01] SUTRO BIOPHARMA, INC. — Other EventsSEC · SEC EDGAR
   Dec 1, 2025 · 8-K
9. [8-K 2.02] SUTRO BIOPHARMA, INC. — Results of Operations and Financial ConditionSEC · SEC EDGAR
   Nov 6, 2025 · 8-K
10. [8-K 2.05] SUTRO BIOPHARMA, INC. — Costs Associated with Exit or Disposal ActivitiesSEC · SEC EDGAR
    Sep 29, 2025 · 8-K
11. [8-K 2.02] SUTRO BIOPHARMA, INC. — Results of Operations and Financial ConditionSEC · SEC EDGAR
    Aug 7, 2025 · 8-K
12. [8-K 3.01] SUTRO BIOPHARMA, INC. — Notice of Delisting or Failure to Satisfy a Continued Listing RuleSEC · SEC EDGAR
    Jun 20, 2025 · 8-K

What would change our view

Research, not tips. No buy/sell recommendations, no price forecasts. Every score is derived from public filings and market data — figures round to whole numbers and refresh each trading day.